CatalYm GmbH

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

The pharmaceutical, biotech and other allied industries came together in London on 4 December to celebrate another year of exceptional achievement at the 20th Annual Scrip Awards at the Raffles hotel

Venture capital investment in biopharmaceutical companies dropped by more than $1bn from the second to the third quarter, according to the latest data from Evaluate, but the amount of VC dollars inves

An impressive readout at the American Society of Clinical Oncology meeting in Chicago last month for its lead asset visugromab has proved to be a big financial inflection point for CatalYm GmbH . The